This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kornmann, M. Articles by Korc, M. Search for Related Content PubMed PubMed Citation Articles by Kornmann, M. Articles by Korc, M.

Inhibition of Cyclin D1 Expression in Human Pancreatic Cancer Cells Is Associated with Increased Chemosensitivity and Decreased Expression of Multiple Chemoresistance Genes¹

Division of Endocrinology, Diabetes and Metabolism, Departments of Medicine, Biological Chemistry, and Pharmacology, University of California, Irvine, California 92697 [M. Korn., M. Korc]; Department of Biochemistry, Kenneth Norris Jr. Cancer Hospital and Research Institute, University of Southern California School of Medicine, Los Angeles, California 90033 [K. D. D., P. V. D.]; Department of Gastroenterology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, 64239 Israel [N. A.]; and Department of General Surgery, University of Ulm, 89075 Ulm, Germany [H. G. B.]

Cyclin D1 belongs to a family of protein kinases that have been implicated in cell cycle regulation. Inhibition of cyclin D1 expression has been recently shown (M. Kornmann, et al., J. Clin. Invest., 101: 344–352, 1998) to suppress pancreatic cancer cell growth and increase cytotoxic actions of cisplatinum. The aim of the present study was to determine whether inhibition of cyclin D1 expression also modulates the effects of other antineoplastic drugs and whether it is associated with alterations in the level of expression of drug resistance genes. The suppression of cyclin D1 expression after the stable transfection of a cyclin D1 antisense construct in PANC-1 and COLO-357 human pancreatic cancer cells resulted in a significant increase in sensitivity to the fluoropyrimidines 5-fluorouracil and 5-fluoro-2'-deoxyuridine and to mitoxantrone. All of the antisense-expressing clones exhibited a decrease in thymidylate synthase and an increase in thymidine phosphorylase mRNA expression as determined by reverse transcription-PCR analysis and decreased levels of MDR-1 and MRP mRNA as determined by Northern blotting. These findings demonstrate that the inhibition of cyclin D1, in addition to suppressing the growth of pancreatic cancer cells, enhances their responsiveness to multiple chemotherapeutic agents and suggest that this effect may be due to the altered expression of several chemoresistance genes.

This article has been cited by other articles:

				B. Sung, A. B. Kunnumakkara, G. Sethi, P. Anand, S. Guha, and B. B. Aggarwal Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model Mol. Cancer Ther., April 1, 2009; 8(4): 959 - 970. [Abstract] [Full Text] [PDF]

				A. Matsushita, T. Gotze, and M. Korc Hepatocyte Growth Factor Mediated Cell Invasion in Pancreatic Cancer Cells Is Dependent on Neuropilin-1 Cancer Res., November 1, 2007; 67(21): 10309 - 10316. [Abstract] [Full Text] [PDF]

				S. Michienzi, B. Bucci, C. Verga Falzacappa, V. Patriarca, A. Stigliano, L. Panacchia, E. Brunetti, V. Toscano, and S. Misiti 3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy J. Endocrinol., May 1, 2007; 193(2): 209 - 223. [Abstract] [Full Text] [PDF]

				H.-S. Shiah, W. Gao, D. C. Baker, and Y.-C. Cheng Inhibition of cell growth and nuclear factor-{kappa}B activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503. Mol. Cancer Ther., October 1, 2006; 5(10): 2484 - 2493. [Abstract] [Full Text] [PDF]

				T. Liersch, C. Langer, B. M. Ghadimi, B. Kulle, D. E. Aust, G. B. Baretton, W. Schwabe, P. Hausler, H. Becker, and C. Jakob Lymph Node Status and TS Gene Expression Are Prognostic Markers in Stage II/III Rectal Cancer After Neoadjuvant Fluorouracil-Based Chemoradiotherapy J. Clin. Oncol., September 1, 2006; 24(25): 4062 - 4068. [Abstract] [Full Text] [PDF]

				M. Yasui, H. Yamamoto, C. Y. Ngan, B. Damdinsuren, Y. Sugita, H. Fukunaga, J. Gu, M. Maeda, I. Takemasa, M. Ikeda, et al. Antisense to Cyclin D1 Inhibits Vascular Endothelial Growth Factor-Stimulated Growth of Vascular Endothelial Cells: Implication of Tumor Vascularization Clin. Cancer Res., August 1, 2006; 12(15): 4720 - 4729. [Abstract] [Full Text] [PDF]

				G. I. Shapiro Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment J. Clin. Oncol., April 10, 2006; 24(11): 1770 - 1783. [Abstract] [Full Text] [PDF]

				H. T. Yip, R. Chopra, R. Chakrabarti, M. S. Veena, B. Ramamurthy, E. S. Srivatsan, and M. B. Wang Cisplatin-Induced Growth Arrest of Head and Neck Cancer Cells Correlates With Increased Expression of p16 and p53. Arch Otolaryngol Head Neck Surg, March 1, 2006; 132(3): 317 - 326. [Abstract] [Full Text] [PDF]

				J. A. Diehl and S. Benzeno Cyclin D1 and Pancreatic Carcinoma: A Proliferative Agonist and Chemotherapeutic Antagonist Clin. Cancer Res., August 15, 2005; 11(16): 5665 - 5667. [Full Text] [PDF]

				H. Biliran Jr., Y. Wang, S. Banerjee, H. Xu, H. Heng, A. Thakur, A. Bollig, F. H. Sarkar, and J. D. Liao Overexpression of Cyclin D1 Promotes Tumor Cell Growth and Confers Resistance to Cisplatin-Mediated Apoptosis in an Elastase-myc Transgene-Expressing Pancreatic Tumor Cell Line Clin. Cancer Res., August 15, 2005; 11(16): 6075 - 6086. [Abstract] [Full Text] [PDF]

				Y. Ma, Q. Feng, D. Sekula, J. A. Diehl, S. J. Freemantle, and E. Dmitrovsky Retinoid Targeting of Different D-Type Cyclins through Distinct Chemopreventive Mechanisms Cancer Res., July 15, 2005; 65(14): 6476 - 6483. [Abstract] [Full Text] [PDF]

				N. B. Arnold, K. Ketterer, J. Kleeff, H. Friess, M. W. Buchler, and M. Korc Thioredoxin Is Downstream of Smad7 in a Pathway That Promotes Growth and Suppresses Cisplatin-Induced Apoptosis in Pancreatic Cancer Cancer Res., May 15, 2004; 64(10): 3599 - 3606. [Abstract] [Full Text] [PDF]

				M. Kornmann, W. Schwabe, S. Sander, M. Kron, J. Strater, S. Polat, E. Kettner, H. F. Weiser, W. Baumann, H. Schramm, et al. Thymidylate Synthase and Dihydropyrimidine Dehydrogenase mRNA Expression Levels: Predictors for Survival in Colorectal Cancer Patients Receiving Adjuvant 5-Fluorouracil Clin. Cancer Res., September 15, 2003; 9(11): 4116 - 4124. [Abstract] [Full Text] [PDF]

				O. Rey, J. Yuan, S. H. Young, and E. Rozengurt Protein Kinase C{nu}/Protein Kinase D3 Nuclear Localization, Catalytic Activation, and Intracellular Redistribution in Response to G Protein-coupled Receptor Agonists J. Biol. Chem., June 20, 2003; 278(26): 23773 - 23785. [Abstract] [Full Text] [PDF]

				S. Guha, J. A. Lunn, C. Santiskulvong, and E. Rozengurt Neurotensin Stimulates Protein Kinase C-dependent Mitogenic Signaling in Human Pancreatic Carcinoma Cell Line PANC-1 Cancer Res., May 15, 2003; 63(10): 2379 - 2387. [Abstract] [Full Text] [PDF]

				J.-i. Hanai, M. Dhanabal, S. A. Karumanchi, C. Albanese, M. Waterman, B. Chan, R. Ramchandran, R. Pestell, and V. P. Sukhatme Endostatin Causes G1 Arrest of Endothelial Cells through Inhibition of Cyclin D1 J. Biol. Chem., May 3, 2002; 277(19): 16464 - 16469. [Abstract] [Full Text] [PDF]

				S. Guha, O. Rey, and E. Rozengurt Neurotensin Induces Protein Kinase C-dependent Protein Kinase D Activation and DNA Synthesis in Human Pancreatic Carcinoma Cell Line PANC-1 Cancer Res., March 1, 2002; 62(6): 1632 - 1640. [Abstract] [Full Text] [PDF]

				H. Zembutsu, Y. Ohnishi, T. Tsunoda, Y. Furukawa, T. Katagiri, Y. Ueyama, N. Tamaoki, T. Nomura, O. Kitahara, R. Yanagawa, et al. Genome-wide cDNA Microarray Screening to Correlate Gene Expression Profiles with Sensitivity of 85 Human Cancer Xenografts to Anticancer Drugs Cancer Res., January 1, 2002; 62(2): 518 - 527. [Abstract] [Full Text] [PDF]

				M. Masuda, M. Suzui, and I. B. Weinstein Effects of Epigallocatechin-3-gallate on Growth, Epidermal Growth Factor Receptor Signaling Pathways, Gene Expression, and Chemosensitivity in Human Head and Neck Squamous Cell Carcinoma Cell Lines Clin. Cancer Res., December 1, 2001; 7(12): 4220 - 4229. [Abstract] [Full Text] [PDF]

				M. T. Yip-Schneider, C. J. Sweeney, S.-H. Jung, P. L. Crowell, and M. S. Marshall Cell Cycle Effects of Nonsteroidal Anti-Inflammatory Drugs and Enhanced Growth Inhibition in Combination with Gemcitabine in Pancreatic Carcinoma Cells J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 976 - 985. [Abstract] [Full Text]

				K. M. Anderson and J. E. Harris Selected Features of Nonendocrine Pancreatic Cancer Experimental Biology and Medicine, June 1, 2001; 226(6): 521 - 537. [Abstract] [Full Text] [PDF]

				H. Uto, A. Ido, A. Moriuchi, Y. Onaga, K. Nagata, M. Onaga, Y. Tahara, T. Hori, S. Hirono, K. Hayashi, et al. Transduction of Antisense Cyclin D1 Using Two-step Gene Transfer Inhibits the Growth of Rat Hepatoma Cells Cancer Res., June 1, 2001; 61(12): 4779 - 4783. [Abstract] [Full Text] [PDF]

				M. E. Laurance, D. B. Starr, E. F. Michelotti, E. Cheung, C. Gonzalez, A. W. Tam, J. Deikman, C. A. Edwards, and A. J. Bardwell Specific down-regulation of an engineered human cyclin D1 promoter by a novel DNA-binding ligand in intact cells Nucleic Acids Res., February 1, 2001; 29(3): 652 - 661. [Abstract] [Full Text] [PDF]

				T. Nakashima and G. L. Clayman Antisense Inhibition of Cyclin D1 in Human Head and Neck Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, August 1, 2000; 126(8): 957 - 961. [Abstract] [Full Text] [PDF]

				T. Niki, S. Iba, M. Tokunou, T. Yamada, Y. Matsuno, and S. Hirohashi Expression of Vascular Endothelial Growth Factors A, B, C, and D and Their Relationships to Lymph Node Status in Lung Adenocarcinoma Clin. Cancer Res., June 1, 2000; 6(6): 2431 - 2439. [Abstract] [Full Text]

				I.B. Weinstein Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis Carcinogenesis, May 1, 2000; 21(5): 857 - 864. [Abstract] [Full Text] [PDF]